Clinical Trials

Clinical Trial Detail

Return to search results.

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma

Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Melanoma

Research Study Number       9103A
    
Principal Investigator       Kim Margolin, MD
    
Phase       I

Look up trial at NIH

Research Study Description

The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced melanoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       9103A
    
Contact       Kelly Yim
    
Telephone       206/288-7370
    
   

Keywords
Melanoma; Solid Tumors; Neuroendocrine Tumor

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials